SNP-ACTH (1-39) Gel
/ Cerium Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 26, 2026
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
(clinicaltrials.gov)
- P3 | N=148 | Recruiting | Sponsor: Cerium Pharmaceuticals, Inc. | Trial completion date: Mar 2026 ➔ Dec 2027 | Trial primary completion date: Mar 2025 ➔ Apr 2027
Head-to-Head • Trial completion date • Trial primary completion date • Glomerulonephritis • Renal Disease
June 05, 2023
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
(clinicaltrials.gov)
- P3 | N=148 | Recruiting | Sponsor: Cerium Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Head-to-Head • Glomerulonephritis • Renal Disease
January 25, 2023
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
(clinicaltrials.gov)
- P3 | N=148 | Not yet recruiting | Sponsor: Cerium Pharmaceuticals, Inc.
FDA event • Head-to-Head • New P3 trial • Glomerulonephritis • Renal Disease
1 to 3
Of
3
Go to page
1